Keyword Index

A

  • Acute Alpha-Methyldopa-induced hepatitis during pregnancy [2.2, Issue 2, 2018, Pages 15-16]
  • Acute kidney injury Hepatorenal Syndrome: Update on pathogenesis and management [2.2, Issue 2, 2018, Pages 7-14]
  • Acute oesophageal variceal haemorrhage Incidence and predictors of acute oesophageal variceal haemorrhage in patients with spontaneous bacterial peritonitis [7.1, Issue 1, 2022, Pages 1-7]
  • Acute on chronic liver failure Acute on chronic hepatic failure due to hepatitis B infection: A case report [5.3, Issue 3, 2021, Pages 27-31]
  • Acute on chronic liver failure ACUTE ON CHRONIC HEPATIC FAILURE DUE TO HEPATITS B INFECTION [(Articles in Press)]
  • Acute on chronic liver failure Cut-off level of serum caspase-cleaved CK 18 (M30) for diagnosis of acute on chronic liver failure in chronic hepatitis C cirrhosis [8.1, Issue 1, 2024, Pages 1-7]
  • AFP Serum fibroblast growth factor 19 and calcium channel α2δ1 subunit as diagnostic biomarkers for hepatocellular carcinoma [9.1, Issue 1, 2025, Pages 9-14]
  • AIH Predictors of mortality in a large cohort of patients with acute hepatitis in a Low Middle-Income Country [8.2, Issue 2, 2024, Pages 9-10]
  • Alpha fetoprotein Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy [4.2, Issue 2, 2020, Pages 69-73]
  • Alpha fetoprotein Incidence of hepatocellular carcinoma one year after direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis; A multicenter study [6.2, Issue 2, 2022, Pages 11-17]
  • Alpha fetoprotein (AFP) The effect of melatonin on apoptosis in hepatocellular carcinoma cell line: An experimental study [3.2, Issue 2, 2019, Pages 75-79]
  • Alpha-Methyldopa Alpha-Methyldopa-induced hepatitis during pregnancy [2.2, Issue 2, 2018, Pages 15-16]
  • Antigen Quantitation Hepatitis B Surface Antigen Quantitation as a Predictor of Treatment Response in Chronic Hepatitis B [2.1, Issue 1, 2016, Pages 1-11]
  • APRI The 13C-Aminopyrine Breath Test Predicts Advanced Fibrosis in Patients with Chronic Hepatitis C: A Pilot Study [2.1, Issue 1, 2016, Pages 1-8]
  • Ascites and gram-negative enteric organisms Spontaneous Bacterial Peritonitis: An Overview [3.1, Issue 1, 2018, Pages 13-17]
  • Ascitic fluid infections Culture negative neutrocytic ascites versus culture positive spontaneous bacterial peritonitis; Is there a Difference; A Multi-Centric Study [5.3, Issue 3, 2021, Pages 1-7]

B

  • B-cell monoclonal lymphocytosis B-cell monoclonal lymphocytosis in chronic hepatitis C virus infection [3.1, Issue 1, 2018, Pages 27-35]
  • Bilharziasis Transient elastography (FibroScan) is not useful in the diagnosis of schistosomal hepatic fibrosis [1.2, Issue 2, 2016, Pages 1-10]
  • Blood transfusion Screening of Occult Hepatitis B Virus Infection among Egyptian Blood Donors. [5.2, Issue 2, 2021, Pages 27-31]

C

  • Carnett´s sign Management of chronic abdominal wall pain: A one-year study [5.1, Issue 1, 2020, Pages 33-40]
  • Caroli’s disease Simple-type Caroli disease with diffuse involvement of the liver: A case report [3.1, Issue 1, 2018, Pages 1-4]
  • Castleman disease Castleman disease as an unusual cause of ascites : Case report [6.2, Issue 2, 2022, Pages 1-3]
  • Cellular carcinoma Hepatitis B Surface Antigen Quantitation as a Predictor of Treatment Response in Chronic Hepatitis B [2.1, Issue 1, 2016, Pages 1-11]
  • Child score Impact of long-term eradication of chronic Hepatitis C infection using the direct-acting antiviral treatment on liver fibrosis parameters in Egyptian patients [7.1, Issue 1, 2022, Pages 21-32]
  • Choledocholithiasis The Role of Endoscopic Ultrasound in Patients with Choledocholithiasis: A pilot study [(Articles in Press)]
  • Cholelithiasis The Role of Endoscopic Ultrasound in Patients with Choledocholithiasis: A pilot study [(Articles in Press)]
  • Cholestasis Cholestatic hepatitis in patient treated by carbimazole: A case report [4.2, Issue 2, 2020, Pages 53-55]
  • Chronic hepatitis The role of interleukin-2 and interleukin-4 in disease progression in patients with schistosomiasis combined with chronic viral hepatitis C and chronic viral hepatitis B [3.2, Issue 2, 2019, Pages 57-64]
  • Chronic hepatitis Prevalence of occult HCV infections in Saudi patients who achieved sustained virologic response with direct acting antiviral treatment [5.1, Issue 1, 2020, Pages 7-12]
  • Chronic hepatitis Prevalence of Occult HCV Infections in Saudi Patients who Achieved Sustained Virologic Response with Direct Acting Antiviral Treatment [(Articles in Press)]
  • Chronic hepatitis Cut-off level of serum caspase-cleaved CK 18 (M30) for diagnosis of acute on chronic liver failure in chronic hepatitis C cirrhosis [8.1, Issue 1, 2024, Pages 1-7]
  • Chronic hepatitis B Demographics of incidentally diagnosed chronic hepatitis B in teenagers in Bangladesh [1.1, Issue 1, 2015, Pages 1-9]
  • Chronic hepatitis B Hepatitis B Surface Antigen Quantitation as a Predictor of Treatment Response in Chronic Hepatitis B [2.1, Issue 1, 2016, Pages 1-11]
  • Chronic hepatitis B Noninvasive markers for staging fibrosis in chronic hepatitis B patients [2.2, Issue 2, 2018, Pages 17-23]
  • Chronic hepatitis C Interferon-ë rs12979860CC genotype predicts sustained virological response to therapy in patients with chronic hepatitis C Genotype 4 but enhances hepatic fibrosis [1.2, Issue 2, 2016, Pages 1-12]
  • Chronic hepatitis C The 13C-Aminopyrine Breath Test Predicts Advanced Fibrosis in Patients with Chronic Hepatitis C: A Pilot Study [2.1, Issue 1, 2016, Pages 1-8]
  • Chronic hepatitis C Comparison between Transient Elastography (FibroScan) and Liver Biopsy for the Diagnosis of Hepatic Fibrosis in Chronic Hepatitis C Patients [2.1, Issue 1, 2016, Pages 1-9]
  • Chronic hepatitis C Comparison between transient elastography and other markers for predicting the fibrosis stages of patients with chronic HCV infection in Beni-Suef governorate, Egypt [4.1, Issue 1, 2019, Pages 45-52]
  • Chronic hepatitis C Evaluation of liver stiffness by non-invasive methods after eradication of HCV by direct-acting antiviral therapy: a retrospective observational study [6.3, Issue 3, 2022, Pages 5-11]
  • Chronic hepatitis C Health-Related Quality of Life after Direct Acting Antiviral Treatment for Chronic Hepatitis C in a community Led Program [7.2, Issue 2, 2023, Pages 9-14]
  • Chronic hepatitis C Hepatocellular carcinoma before and after the era of direct-acting antiviral therapy for chronic hepatitis C: Dose the story differ? [8.1, Issue 1, 2024, Pages 17-22]
  • Chronic hepatitis C virus Recent trends in chronic hepatitis C virus treatment [2.2, Issue 2, 2018, Pages 1-6]
  • Chronic liver disease Periodontal disease as predictor of chronic liver diseases [4.2, Issue 2, 2020, Pages 57-61]
  • Chronic liver disease Impact of COVID-19 on mortality rate in patients with chronic liver diseases, single-centre observational study [7.2, Issue 2, 2023, Pages 15-22]
  • Chronic liver diseases Is there is a link between oral microbiome and chronic liver diseases [6.3, Issue 3, 2022, Pages 19-21]
  • Cirrhosis Spontaneous Bacterial Peritonitis: An Overview [3.1, Issue 1, 2018, Pages 13-17]
  • Cirrhosis Infections in cirrhotic patients [4.1, Issue 1, 2019, Pages 5-14]
  • Cirrhosis Portal Hypertension, an Overview [4.1, Issue 1, 2019, Pages 15-21]
  • Cirrhosis Management of chronic hepatitis B in special populations [4.2, Issue 2, 2020, Pages 63-68]
  • Cirrhosis Serum Thioredoxin as a Diagnostic Marker for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 9-15]
  • Cirrhosis Macrophage Inflammatory Protein Type 1 Beta as a Novel Diagnostic Marker for Diagnosis of Spontaneous Bacterial Peritonitis [5.2, Issue 2, 2021, Pages 16-20]
  • Cirrhosis Score C-reactive protein to albumin ratio: A new score for predicting the recurrence of spontaneous bacterial peritonitis in cirrhotic patients with ascites [8.2, Issue 2, 2024, Pages 6-8]
  • Coagulopathy Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]
  • Coinfection Seroprevalence of hepatitis A virus infection in patients with chronic liver diseases: Do we need to vaccinate? [1.1, Issue 1, 2015, Pages 1-9]
  • Colorectal carcinoma Evaluation of the causes and outcome of lower gastrointestinal bleeding: An endoscopic study [3.1, Issue 1, 2018, Pages 19-25]
  • Common bile duct stones The role of endoscopic ultrasound in patients with choledocholithiasis: A pilot study [4.2, Issue 2, 2020, Pages 81-86]
  • Complications Nutritional status in cirrhosis; pathogenesis and management [3.2, Issue 2, 2019, Pages 41-47]
  • Coronavirus disease Intracranial hemorrhage with COVID 19 patient; case report [5.1, Issue 1, 2020, Pages 3-5]
  • Coronavirus disease Misuse of anticoagulants in COVID-19 patient: A case of gastrointestinal bleeding [5.2, Issue 2, 2021, Pages 1-2]
  • COVID-19 Impact of COVID-19 pandemic on hospital admission for endoscopy unit; single center study [5.1, Issue 1, 2020, Pages 41-45]
  • COVID-19 Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]
  • COVID-19 Impact of COVID-19 on mortality rate in patients with chronic liver diseases, single-centre observational study [7.2, Issue 2, 2023, Pages 15-22]
  • COVID-19 Mortality risk and associated factors in cirrhosis patients with SARS-CoV-2 infection [8.1, Issue 1, 2024, Pages 9-16]
  • C reactive protein Diagnostic utility of absolute neutrophil count as a new marker of spontaneous bacterial peritonitis; multicenter study [6.3, Issue 3, 2022, Pages 12-18]
  • C-reactive protein C-reactive protein to albumin ratio: A new score for predicting the recurrence of spontaneous bacterial peritonitis in cirrhotic patients with ascites [8.2, Issue 2, 2024, Pages 6-8]
  • C-reactive protein to albumin score C-reactive protein to albumin ratio: A new score for predicting the recurrence of spontaneous bacterial peritonitis in cirrhotic patients with ascites [8.2, Issue 2, 2024, Pages 6-8]
  • Crohn’s disease and ulcerative colitis Serum microRNA 106 and microRNA 223 as novel biomarkers in inflammatory bowel disease [5.1, Issue 1, 2020, Pages 19-24]
  • Cytokeratin-18 Value of Cytokeratin-18 as a non-invasive diagnostic biomarker of nonalcoholic steatohepatitis (NASH) [3.2, Issue 2, 2019, Pages 65-74]
  • Cytokeratin-18 Cut-off level of serum caspase-cleaved CK 18 (M30) for diagnosis of acute on chronic liver failure in chronic hepatitis C cirrhosis [8.1, Issue 1, 2024, Pages 1-7]

D

  • DAAs therapy Impact of long-term eradication of chronic Hepatitis C infection using the direct-acting antiviral treatment on liver fibrosis parameters in Egyptian patients [7.1, Issue 1, 2022, Pages 21-32]
  • DAA Treatment Health-Related Quality of Life after Direct Acting Antiviral Treatment for Chronic Hepatitis C in a community Led Program [7.2, Issue 2, 2023, Pages 9-14]
  • Daclatasvir Assessment of Patient Compliance during treatment of chronic hepatitis C infection using Sofosbuvir and Daclatasvir with or without Ribavirin. [5.2, Issue 2, 2021, Pages 32-39]
  • D-Dimer Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]
  • Diabetes mellitus Characterization of hepatocellular carcinoma in Mansoura university Hospitals: A case-control study of risk factors. [6.1, Issue 1, 2021, Pages 38-45]
  • DILI Predictors of mortality in a large cohort of patients with acute hepatitis in a Low Middle-Income Country [8.2, Issue 2, 2024, Pages 9-10]
  • Direct acting antiviral Serum Thioredoxin as a Diagnostic Marker for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 9-15]
  • Direct-acting antiviral agents Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy [4.2, Issue 2, 2020, Pages 69-73]
  • Direct-acting antiviral agents Prevalence of occult HCV infections in Saudi patients who achieved sustained virologic response with direct acting antiviral treatment [5.1, Issue 1, 2020, Pages 7-12]
  • Direct-acting antiviral agents Prevalence of Occult HCV Infections in Saudi Patients who Achieved Sustained Virologic Response with Direct Acting Antiviral Treatment [(Articles in Press)]
  • Direct-acting antiviral agents Outcomes of direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis [6.1, Issue 1, 2021, Pages 46-53]
  • Direct-acting antiviral agents Incidence of hepatocellular carcinoma one year after direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis; A multicenter study [6.2, Issue 2, 2022, Pages 11-17]
  • Direct acting antivirals Impact of Direct-Acting Antiviral Agents Treatment on Body Mass Index and Lipid Profile in Egyptian Chronic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 21-26]
  • Direct acting antivirals Hepatocellular carcinoma before and after the era of direct-acting antiviral therapy for chronic hepatitis C: Dose the story differ? [8.1, Issue 1, 2024, Pages 17-22]
  • Dual infection Seroprevalence of hepatitis A virus infection in patients with chronic liver diseases: Do we need to vaccinate? [1.1, Issue 1, 2015, Pages 1-9]

E

  • Elastography Transient elastography (FibroScan) is not useful in the diagnosis of schistosomal hepatic fibrosis [1.2, Issue 2, 2016, Pages 1-10]
  • Encephalitis Acute Epstein-Barr virus Encephalitis and hepatitis without mononucleosis syndrome: a case report [7.3, Issue 3, 2023, Pages 15-17]
  • Endoscopic retrograde cholangiopancreatography The role of endoscopic ultrasound in patients with choledocholithiasis: A pilot study [4.2, Issue 2, 2020, Pages 81-86]
  • Endoscopic retrograde cholangiopancreatography The Role of Endoscopic Ultrasound in Patients with Choledocholithiasis: A pilot study [(Articles in Press)]
  • Endoscopic ultrasound The role of endoscopic ultrasound in patients with choledocholithiasis: A pilot study [4.2, Issue 2, 2020, Pages 81-86]
  • Endoscopic ultrasound The Role of Endoscopic Ultrasound in Patients with Choledocholithiasis: A pilot study [(Articles in Press)]
  • Endoscopy Impact of COVID-19 pandemic on hospital admission for endoscopy unit; single center study [5.1, Issue 1, 2020, Pages 41-45]
  • Endoscopy Platelet count/spleen diameter ratio as a predictor of high-risk esophageal varices in patients with liver cirrhosis [6.2, Issue 2, 2022, Pages 25-30]
  • Entecavir Fulminant hepatitis by concurrent acute HBV-HCV infection successfully treated with antivirals while seeking for an orthotopic liver transplantation [7.1, Issue 1, 2022, Pages 13-14]
  • Entecavir Outcome of Hepatitis B treatment with oral drugs (Tenofovir and Entecavir) in a tertiary care center in eastern India [8.2, Issue 2, 2024, Pages 17-20]
  • Enzyme replacement therapy and hepatosplenomegaly Gaucher disease: Recent advances in the diagnosis and management. [6.2, Issue 2, 2022, Pages 6-10]
  • Eosinophilic gastroenteritis Eosinophilic ascites: Uncommon Presentation of Eosinophilic Gastroenteritis in children [3.2, Issue 2, 2019, Pages 37-40]
  • Epstein-Barr virus Acute Epstein-Barr virus Encephalitis and hepatitis without mononucleosis syndrome: a case report [7.3, Issue 3, 2023, Pages 15-17]
  • Esophageal varices Transient elastography (FibroScan) is not useful in the diagnosis of schistosomal hepatic fibrosis [1.2, Issue 2, 2016, Pages 1-10]
  • Esophageal varices Platelet count/spleen diameter ratio as a predictor of high-risk esophageal varices in patients with liver cirrhosis [6.2, Issue 2, 2022, Pages 25-30]

F

  • Fatty liver index Influence of liraglutide, dulaglutide versus conventional treatment on fatty liver index and fibrosis-4 score in Egyptian patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease [5.1, Issue 1, 2020, Pages 25-32]
  • Fatty liver index Influence of Liraglutide, Dulaglutide Versus Conventional Treatment on Fatty liver index and Fibrosis-4 Score in Egyptian Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease. [(Articles in Press)]
  • FGF-19 Serum fibroblast growth factor 19 and calcium channel α2δ1 subunit as diagnostic biomarkers for hepatocellular carcinoma [9.1, Issue 1, 2025, Pages 9-14]
  • FIB-4 A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-severe and severe fibrosis in patients with chronic Hepatitis C [1.2, Issue 2, 2016, Pages 1-10]
  • FIB-4 The 13C-Aminopyrine Breath Test Predicts Advanced Fibrosis in Patients with Chronic Hepatitis C: A Pilot Study [2.1, Issue 1, 2016, Pages 1-8]
  • FIB-4 score Influence of liraglutide, dulaglutide versus conventional treatment on fatty liver index and fibrosis-4 score in Egyptian patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease [5.1, Issue 1, 2020, Pages 25-32]
  • FIB-4 score Influence of Liraglutide, Dulaglutide Versus Conventional Treatment on Fatty liver index and Fibrosis-4 Score in Egyptian Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease. [(Articles in Press)]
  • Fibrofast (FIB-5) A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-severe and severe fibrosis in patients with chronic Hepatitis C [1.2, Issue 2, 2016, Pages 1-10]
  • FibroScan The 13C-Aminopyrine Breath Test Predicts Advanced Fibrosis in Patients with Chronic Hepatitis C: A Pilot Study [2.1, Issue 1, 2016, Pages 1-8]
  • FibroScan Comparison between Transient Elastography (FibroScan) and Liver Biopsy for the Diagnosis of Hepatic Fibrosis in Chronic Hepatitis C Patients [2.1, Issue 1, 2016, Pages 1-9]
  • FibroScan Comparison between transient elastography and other markers for predicting the fibrosis stages of patients with chronic HCV infection in Beni-Suef governorate, Egypt [4.1, Issue 1, 2019, Pages 45-52]
  • Fulminant hepatitis Fulminant hepatitis by concurrent acute HBV-HCV infection successfully treated with antivirals while seeking for an orthotopic liver transplantation [7.1, Issue 1, 2022, Pages 13-14]

G

  • Gastric variceal bleeding Predictors of early re-bleeding and mortality in patients with first attack of gastric variceal hemorrhage [5.3, Issue 3, 2021, Pages 14-21]
  • Gastrointestinal bleeding Impact of COVID-19 pandemic on hospital admission for endoscopy unit; single center study [5.1, Issue 1, 2020, Pages 41-45]
  • Gaucher disease Gaucher disease: Recent advances in the diagnosis and management. [6.2, Issue 2, 2022, Pages 6-10]
  • Genetics Interferon-ë rs12979860CC genotype predicts sustained virological response to therapy in patients with chronic hepatitis C Genotype 4 but enhances hepatic fibrosis [1.2, Issue 2, 2016, Pages 1-12]
  • Genotype 4 Interferon-ë rs12979860CC genotype predicts sustained virological response to therapy in patients with chronic hepatitis C Genotype 4 but enhances hepatic fibrosis [1.2, Issue 2, 2016, Pages 1-12]
  • Genotype 4 Sofosbuvir plus Ribavirin for Treatment-Naïve Chronic HCV Genotype 4 Patients: Real-life Experience [2.1, Issue 1, 2016, Pages 1-8]
  • GLP1-RAs Influence of liraglutide, dulaglutide versus conventional treatment on fatty liver index and fibrosis-4 score in Egyptian patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease [5.1, Issue 1, 2020, Pages 25-32]
  • GLP1-RAs Influence of Liraglutide, Dulaglutide Versus Conventional Treatment on Fatty liver index and Fibrosis-4 Score in Egyptian Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease. [(Articles in Press)]

H

  • HBV Seroepidemiology and risk factor of hepatitis B and C virus infections in hemodialysis patients in Lomé, Togo. [5.3, Issue 3, 2021, Pages 22-26]
  • HBV genotype D Liver histopathology detects more chronic hepatitis B virus genotype D patients who need to be treated [1.1, Issue 1, 2015, Pages 1-14]
  • HBV-HCV coinfection Management of chronic hepatitis B in special populations [4.2, Issue 2, 2020, Pages 63-68]
  • HBV Reactivation Management of chronic hepatitis B in special populations [4.2, Issue 2, 2020, Pages 63-68]
  • HCC Serum fibroblast growth factor 19 and calcium channel α2δ1 subunit as diagnostic biomarkers for hepatocellular carcinoma [9.1, Issue 1, 2025, Pages 9-14]
  • HCV Prevalence of occult HCV infections in Saudi patients who achieved sustained virologic response with direct acting antiviral treatment [5.1, Issue 1, 2020, Pages 7-12]
  • HCV Prevalence of Occult HCV Infections in Saudi Patients who Achieved Sustained Virologic Response with Direct Acting Antiviral Treatment [(Articles in Press)]
  • HCV Seroepidemiology and risk factor of hepatitis B and C virus infections in hemodialysis patients in Lomé, Togo. [5.3, Issue 3, 2021, Pages 22-26]
  • HCV Burden of parasitic infection and its impact on growth of children with hepatitis C Virus [6.1, Issue 1, 2021, Pages 17-23]
  • HCV Role of interferon gamma gene polymorphism in spontaneous viral clearance versus chronicity in hepatitis C infected Egyptian patients [6.1, Issue 1, 2021, Pages 24-31]
  • HCV Impact of long-term eradication of chronic Hepatitis C infection using the direct-acting antiviral treatment on liver fibrosis parameters in Egyptian patients [7.1, Issue 1, 2022, Pages 21-32]
  • HCV infection Pentraxin 3 level as a Biomarker for Diagnosis of Hepatitis C Virus Related Hepatocellular Carcinoma [8.2, Issue 2, 2024, Pages 1-7]
  • Health related quality of life Health-Related Quality of Life after Direct Acting Antiviral Treatment for Chronic Hepatitis C in a community Led Program [7.2, Issue 2, 2023, Pages 9-14]
  • Hemodialysis Seroepidemiology and risk factor of hepatitis B and C virus infections in hemodialysis patients in Lomé, Togo. [5.3, Issue 3, 2021, Pages 22-26]
  • Hemoglobin Impact of Direct-Acting Antiviral Agents Treatment on Body Mass Index and Lipid Profile in Egyptian Chronic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 21-26]
  • Hepatic artery resistive index Value of hepatic artery resistive index in evaluation of liver fibrosis related to non-alcoholic fatty liver diseases [7.2, Issue 2, 2023, Pages 1-8]
  • Hepatic failure Acute on chronic hepatic failure due to hepatitis B infection: A case report [5.3, Issue 3, 2021, Pages 27-31]
  • Hepatic failure ACUTE ON CHRONIC HEPATIC FAILURE DUE TO HEPATITS B INFECTION [(Articles in Press)]
  • Hepatic fibrosis Interferon-ë rs12979860CC genotype predicts sustained virological response to therapy in patients with chronic hepatitis C Genotype 4 but enhances hepatic fibrosis [1.2, Issue 2, 2016, Pages 1-12]
  • Hepatitis Alpha-Methyldopa-induced hepatitis during pregnancy [2.2, Issue 2, 2018, Pages 15-16]
  • Hepatitis Acute Epstein-Barr virus Encephalitis and hepatitis without mononucleosis syndrome: a case report [7.3, Issue 3, 2023, Pages 15-17]
  • Hepatitis A Predictors of mortality in a large cohort of patients with acute hepatitis in a Low Middle-Income Country [8.2, Issue 2, 2024, Pages 9-10]
  • Hepatitis A vaccination Seroprevalence of hepatitis A virus infection in patients with chronic liver diseases: Do we need to vaccinate? [1.1, Issue 1, 2015, Pages 1-9]
  • Hepatitis B Infection Acute on chronic hepatic failure due to hepatitis B infection: A case report [5.3, Issue 3, 2021, Pages 27-31]
  • Hepatitis B Infection ACUTE ON CHRONIC HEPATIC FAILURE DUE TO HEPATITS B INFECTION [(Articles in Press)]
  • Hepatitis B Surface Hepatitis B Surface Antigen Quantitation as a Predictor of Treatment Response in Chronic Hepatitis B [2.1, Issue 1, 2016, Pages 1-11]
  • Hepatitis B virus Demographics of incidentally diagnosed chronic hepatitis B in teenagers in Bangladesh [1.1, Issue 1, 2015, Pages 1-9]
  • Hepatitis B virus Hepatitis B Virus: Update in Management [3.2, Issue 2, 2019, Pages 49-56]
  • Hepatitis B virus Management of chronic hepatitis B in special populations [4.2, Issue 2, 2020, Pages 63-68]
  • Hepatitis B virus Screening of Occult Hepatitis B Virus Infection among Egyptian Blood Donors. [5.2, Issue 2, 2021, Pages 27-31]
  • Hepatitis B virus Characterization of hepatocellular carcinoma in Mansoura university Hospitals: A case-control study of risk factors. [6.1, Issue 1, 2021, Pages 38-45]
  • Hepatitis B virus Outcome of Hepatitis B treatment with oral drugs (Tenofovir and Entecavir) in a tertiary care center in eastern India [8.2, Issue 2, 2024, Pages 17-20]
  • Hepatitis C Genotype 4 A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-severe and severe fibrosis in patients with chronic Hepatitis C [1.2, Issue 2, 2016, Pages 1-10]
  • Hepatitis C genotyping HCV Genotype 5a presenting with hepatocellular cancer: First report from India [5.1, Issue 1, 2020, Pages 1-2]
  • Hepatitis C virus Evolution of treatment of chronic hepatitis C virus infection by directly acting anti-viral therapeutics: A glimmer of hope [1.1, Issue 1, 2015, Pages 1-11]
  • Hepatitis C virus Sofosbuvir plus Ribavirin for Treatment-Naïve Chronic HCV Genotype 4 Patients: Real-life Experience [2.1, Issue 1, 2016, Pages 1-8]
  • Hepatitis C virus Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy [4.2, Issue 2, 2020, Pages 69-73]
  • Hepatitis C virus HCV Genotype 5a presenting with hepatocellular cancer: First report from India [5.1, Issue 1, 2020, Pages 1-2]
  • Hepatitis C virus Prevalence of occult HCV infections in Saudi patients who achieved sustained virologic response with direct acting antiviral treatment [5.1, Issue 1, 2020, Pages 7-12]
  • Hepatitis C virus Prevalence of Occult HCV Infections in Saudi Patients who Achieved Sustained Virologic Response with Direct Acting Antiviral Treatment [(Articles in Press)]
  • Hepatitis C virus Genetic Variability of NS5B Region of Hepatitis C Virus in Togo [5.3, Issue 3, 2021, Pages 8-13]
  • Hepatitis C virus Characterization of hepatocellular carcinoma in Mansoura university Hospitals: A case-control study of risk factors. [6.1, Issue 1, 2021, Pages 38-45]
  • Hepatitis C virus Outcomes of direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis [6.1, Issue 1, 2021, Pages 46-53]
  • Hepatitis C virus Incidence of hepatocellular carcinoma one year after direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis; A multicenter study [6.2, Issue 2, 2022, Pages 11-17]
  • Hepatitis C Virus Genotype 4 Fibrogenic/Angiogenic Linker for Non-invasive assessment of hepatic fibrosis staging in chronic hepatitis C genotype 4 patients [2.1, Issue 1, 2016, Pages 1-14]
  • Hepatitis E Predictors of mortality in a large cohort of patients with acute hepatitis in a Low Middle-Income Country [8.2, Issue 2, 2024, Pages 9-10]
  • Hepatocellular carcinoma Characterization of hepatocellular carcinoma in Mansoura university Hospitals: A case-control study of risk factors. [6.1, Issue 1, 2021, Pages 38-45]
  • Hepatocellular carc-inoma HCV Genotype 5a presenting with hepatocellular cancer: First report from India [5.1, Issue 1, 2020, Pages 1-2]
  • Hepatocellular carcinoma MicroRNA 122 as adiagnostic biomarker for hepatitis C- related hepatocellular carcinoma [4.1, Issue 1, 2019, Pages 35-43]
  • Hepatocellular carcinoma Serum Thioredoxin as a Diagnostic Marker for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 9-15]
  • Hepatocellular carcinoma Incidence of hepatocellular carcinoma one year after direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis; A multicenter study [6.2, Issue 2, 2022, Pages 11-17]
  • Hepatocellular carcinoma Diagnostic value of of Long Non-Coding RNA ZFAS1 as a Potential Biomarker for Hepatocellular Carcinoma [6.2, Issue 2, 2022, Pages 18-24]
  • Hepatocellular carcinoma Anti-cancer activity of hesperidin against hepatocellular carcinoma-induced in rats through upregulation of RIPK1 expression [7.1, Issue 1, 2022, Pages 15-20]
  • Hepatocellular carcinoma Hepatocellular carcinoma before and after the era of direct-acting antiviral therapy for chronic hepatitis C: Dose the story differ? [8.1, Issue 1, 2024, Pages 17-22]
  • Hepatocellular carcinoma Pentraxin 3 level as a Biomarker for Diagnosis of Hepatitis C Virus Related Hepatocellular Carcinoma [8.2, Issue 2, 2024, Pages 1-7]
  • Hepatocellular carcinoma Dynamic changes of systemic inflammatory markers and their association with radiologic progression and hepatotoxicity in patients with hepatocellular carcinoma on systemic therapy [9.1, Issue 1, 2025, Pages 1-7]
  • Hepatocellular carcinoma (HCC) The effect of melatonin on apoptosis in hepatocellular carcinoma cell line: An experimental study [3.2, Issue 2, 2019, Pages 75-79]
  • Hepatopulmonary syndrome Hepatopulmonary syndrome: A recent review of the literature [3.1, Issue 1, 2018, Pages 5-12]
  • Hepatorenal syndrome Hepatorenal Syndrome: Update on pathogenesis and management [2.2, Issue 2, 2018, Pages 7-14]
  • Hesperidin Anti-cancer activity of hesperidin against hepatocellular carcinoma-induced in rats through upregulation of RIPK1 expression [7.1, Issue 1, 2022, Pages 15-20]
  • Human albumin Mini-dose albumin can reduce renal impairment in cirrhotic patients with spontaneous bacterial peritonitis [5.1, Issue 1, 2020, Pages 13-18]
  • Hyaluronic acid Fibrogenic/Angiogenic Linker for Non-invasive assessment of hepatic fibrosis staging in chronic hepatitis C genotype 4 patients [2.1, Issue 1, 2016, Pages 1-14]
  • Hyaluronic acid vascular Fibrogenic/Angiogenic Linker for Non-invasive assessment of hepatic fibrosis staging in chronic hepatitis C genotype 4 patients [2.1, Issue 1, 2016, Pages 1-14]
  • Hyperthyroidism and antithyroid drugs Cholestatic hepatitis in patient treated by carbimazole: A case report [4.2, Issue 2, 2020, Pages 53-55]
  • Hypoalbuminemia The Predictive Factors for Recurrence of Spontaneous Bacterial Peritonitis [2.2, Issue 2, 2018, Pages 25-29]

I

  • IFN- γ gene polymorphism Role of interferon gamma gene polymorphism in spontaneous viral clearance versus chronicity in hepatitis C infected Egyptian patients [6.1, Issue 1, 2021, Pages 24-31]
  • Infection Infections in cirrhotic patients [4.1, Issue 1, 2019, Pages 5-14]
  • Infection Periodontal disease as predictor of chronic liver diseases [4.2, Issue 2, 2020, Pages 57-61]
  • Insulin Resistance Metabolic dysfunction-associated fatty liver disease from definition to complications [6.1, Issue 1, 2021, Pages 4-9]
  • Interleukin-28B Interferon-ë rs12979860CC genotype predicts sustained virological response to therapy in patients with chronic hepatitis C Genotype 4 but enhances hepatic fibrosis [1.2, Issue 2, 2016, Pages 1-12]

L

  • Lipid profile Impact of Direct-Acting Antiviral Agents Treatment on Body Mass Index and Lipid Profile in Egyptian Chronic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 21-26]
  • Liver Biopsy A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-severe and severe fibrosis in patients with chronic Hepatitis C [1.2, Issue 2, 2016, Pages 1-10]
  • Liver Biopsy Comparison between Transient Elastography (FibroScan) and Liver Biopsy for the Diagnosis of Hepatic Fibrosis in Chronic Hepatitis C Patients [2.1, Issue 1, 2016, Pages 1-9]
  • Liver Biopsy B-cell monoclonal lymphocytosis in chronic hepatitis C virus infection [3.1, Issue 1, 2018, Pages 27-35]
  • Liver cirrhosis Hepatorenal Syndrome: Update on pathogenesis and management [2.2, Issue 2, 2018, Pages 7-14]
  • Liver cirrhosis Assessment of muscle status and Sarcopenia in patients with liver cirrhosis [4.1, Issue 1, 2019, Pages 23-33]
  • Liver cirrhosis Frequency and characterization of mixed ascites among cirrhotic patients admitted to Zagazig University hospital [4.2, Issue 2, 2020, Pages 75-80]
  • Liver cirrhosis Diagnostic value of of Long Non-Coding RNA ZFAS1 as a Potential Biomarker for Hepatocellular Carcinoma [6.2, Issue 2, 2022, Pages 18-24]
  • Liver cirrhosis Platelet count/spleen diameter ratio as a predictor of high-risk esophageal varices in patients with liver cirrhosis [6.2, Issue 2, 2022, Pages 25-30]
  • Liver cirrhosis Tertiary peritonitis in patients with cirrhotic ascites; Case report [6.3, Issue 3, 2022, Pages 29-31]
  • Liver cirrhosis Incidence and predictors of acute oesophageal variceal haemorrhage in patients with spontaneous bacterial peritonitis [7.1, Issue 1, 2022, Pages 1-7]
  • Liver fibrosis A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-severe and severe fibrosis in patients with chronic Hepatitis C [1.2, Issue 2, 2016, Pages 1-10]
  • Liver fibrosis Transient elastography (FibroScan) is not useful in the diagnosis of schistosomal hepatic fibrosis [1.2, Issue 2, 2016, Pages 1-10]
  • Liver fibrosis Fibrogenic/Angiogenic Linker for Non-invasive assessment of hepatic fibrosis staging in chronic hepatitis C genotype 4 patients [2.1, Issue 1, 2016, Pages 1-14]
  • Liver fibrosis Noninvasive markers for staging fibrosis in chronic hepatitis B patients [2.2, Issue 2, 2018, Pages 17-23]
  • Liver fibrosis B-cell monoclonal lymphocytosis in chronic hepatitis C virus infection [3.1, Issue 1, 2018, Pages 27-35]
  • Liver fibrosis Comparison between transient elastography and other markers for predicting the fibrosis stages of patients with chronic HCV infection in Beni-Suef governorate, Egypt [4.1, Issue 1, 2019, Pages 45-52]
  • Liver fibrosis parameters Impact of long-term eradication of chronic Hepatitis C infection using the direct-acting antiviral treatment on liver fibrosis parameters in Egyptian patients [7.1, Issue 1, 2022, Pages 21-32]
  • Liver Stiffness Evaluation of liver stiffness by non-invasive methods after eradication of HCV by direct-acting antiviral therapy: a retrospective observational study [6.3, Issue 3, 2022, Pages 5-11]
  • Liver stiffness measurement Comparison between transient elastography and other markers for predicting the fibrosis stages of patients with chronic HCV infection in Beni-Suef governorate, Egypt [4.1, Issue 1, 2019, Pages 45-52]
  • Liver stiffness measurement Value of hepatic artery resistive index in evaluation of liver fibrosis related to non-alcoholic fatty liver diseases [7.2, Issue 2, 2023, Pages 1-8]
  • Liver transplantation Nutritional status in cirrhosis; pathogenesis and management [3.2, Issue 2, 2019, Pages 41-47]
  • Lower gastrointestinal bleeding Evaluation of the causes and outcome of lower gastrointestinal bleeding: An endoscopic study [3.1, Issue 1, 2018, Pages 19-25]

M

  • Medicare and Medicaid Services Predictors of 30-day hospital readmission in patients with spontaneous bacterial peritonitis, to improve health quality. Prospective cohort [7.3, Issue 3, 2023, Pages 7-14]
  • Melatonin The effect of melatonin on apoptosis in hepatocellular carcinoma cell line: An experimental study [3.2, Issue 2, 2019, Pages 75-79]
  • MELD Impact of long-term eradication of chronic Hepatitis C infection using the direct-acting antiviral treatment on liver fibrosis parameters in Egyptian patients [7.1, Issue 1, 2022, Pages 21-32]
  • Metabolic Metabolic Associated Fatty Liver Disease as the New Nomenclature for Nonalcoholic Fatty Liver Disease [6.2, Issue 2, 2022, Pages 4-5]
  • Metabolic associated fatty liver disease Metabolic Associated Fatty Liver Disease as the New Nomenclature for Nonalcoholic Fatty Liver Disease [6.2, Issue 2, 2022, Pages 4-5]
  • Metabolic associated fatty liver disease Transient Elastography and its Correlation with Biochemical Scores in patients with Metabolic associated fatty liver disease [6.3, Issue 3, 2022, Pages 22-28]
  • Metabolic dysfunction-associated fatty liver disease Metabolic dysfunction-associated fatty liver disease from definition to complications [6.1, Issue 1, 2021, Pages 4-9]
  • Mixed ascites Frequency and characterization of mixed ascites among cirrhotic patients admitted to Zagazig University hospital [4.2, Issue 2, 2020, Pages 75-80]

N

  • NAFLD Value of Cytokeratin-18 as a non-invasive diagnostic biomarker of nonalcoholic steatohepatitis (NASH) [3.2, Issue 2, 2019, Pages 65-74]
  • NAFLD Influence of liraglutide, dulaglutide versus conventional treatment on fatty liver index and fibrosis-4 score in Egyptian patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease [5.1, Issue 1, 2020, Pages 25-32]
  • NAFLD Influence of Liraglutide, Dulaglutide Versus Conventional Treatment on Fatty liver index and Fibrosis-4 Score in Egyptian Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease. [(Articles in Press)]
  • NAFLD fibrosis score Value of hepatic artery resistive index in evaluation of liver fibrosis related to non-alcoholic fatty liver diseases [7.2, Issue 2, 2023, Pages 1-8]
  • Nano zinc oxide Nanoparticle zinc oxide obviates oxidative stress of liver cells in induced-diabetes mellitus model [7.1, Issue 1, 2022, Pages 8-12]
  • NASH Value of Cytokeratin-18 as a non-invasive diagnostic biomarker of nonalcoholic steatohepatitis (NASH) [3.2, Issue 2, 2019, Pages 65-74]
  • Nomenclature Metabolic Associated Fatty Liver Disease as the New Nomenclature for Nonalcoholic Fatty Liver Disease [6.2, Issue 2, 2022, Pages 4-5]
  • Non-alcoholic fatty liver disease Metabolic dysfunction-associated fatty liver disease from definition to complications [6.1, Issue 1, 2021, Pages 4-9]
  • Non-alcoholic fatty liver disease Multi-parametric magnetic resonance imaging as a diagnostic tool of hepatic steatosis for non-alcoholic fatty liver disease in Egyptian patients. [6.1, Issue 1, 2021, Pages 32-37]
  • Nonalcoholic fatty liver disease Metabolic Associated Fatty Liver Disease as the New Nomenclature for Nonalcoholic Fatty Liver Disease [6.2, Issue 2, 2022, Pages 4-5]
  • Nonalcoholic fatty liver disease Value of hepatic artery resistive index in evaluation of liver fibrosis related to non-alcoholic fatty liver diseases [7.2, Issue 2, 2023, Pages 1-8]
  • Non-A/non-E hepatitis Predictors of mortality in a large cohort of patients with acute hepatitis in a Low Middle-Income Country [8.2, Issue 2, 2024, Pages 9-10]
  • Non-Coding RNA ZFAS1 Diagnostic value of of Long Non-Coding RNA ZFAS1 as a Potential Biomarker for Hepatocellular Carcinoma [6.2, Issue 2, 2022, Pages 18-24]
  • Non-Hodgkin lymphoma Non Hodgkin lymphoma of the cecum; case report [4.1, Issue 1, 2019, Pages 1-4]
  • Noninvasive markers Noninvasive markers for staging fibrosis in chronic hepatitis B patients [2.2, Issue 2, 2018, Pages 17-23]
  • Non-invasive measures Transient elastography (FibroScan) is not useful in the diagnosis of schistosomal hepatic fibrosis [1.2, Issue 2, 2016, Pages 1-10]
  • Nucleoside/nucleotide analogues and hepatitis B vaccine Hepatitis B Virus: Update in Management [3.2, Issue 2, 2019, Pages 49-56]
  • Nucleos(t)ide analogues and dental practice Management of chronic hepatitis B in special populations [4.2, Issue 2, 2020, Pages 63-68]
  • Nutritional Status Nutritional status in cirrhosis; pathogenesis and management [3.2, Issue 2, 2019, Pages 41-47]

O

  • Occult HCV Infection Prevalence of occult HCV infections in Saudi patients who achieved sustained virologic response with direct acting antiviral treatment [5.1, Issue 1, 2020, Pages 7-12]
  • Occult HCV Infection Prevalence of Occult HCV Infections in Saudi Patients who Achieved Sustained Virologic Response with Direct Acting Antiviral Treatment [(Articles in Press)]
  • Oesophageal varices Incidence and predictors of acute oesophageal variceal haemorrhage in patients with spontaneous bacterial peritonitis [7.1, Issue 1, 2022, Pages 1-7]
  • Oral microbiome Is there is a link between oral microbiome and chronic liver diseases [6.3, Issue 3, 2022, Pages 19-21]
  • Oxidative Stress Anti-cancer activity of hesperidin against hepatocellular carcinoma-induced in rats through upregulation of RIPK1 expression [7.1, Issue 1, 2022, Pages 15-20]

P

  • Pancreatectomy and endoscopic ultrasound The Endoscopic Ultrasound Evaluation of Pancreatic Cystic Lesions [8.1, Issue 1, 2024, Pages 23-28]
  • Pancreatic cystic lesions The Endoscopic Ultrasound Evaluation of Pancreatic Cystic Lesions [8.1, Issue 1, 2024, Pages 23-28]
  • Pathology Liver histopathology detects more chronic hepatitis B virus genotype D patients who need to be treated [1.1, Issue 1, 2015, Pages 1-14]
  • Pediatrics Burden of parasitic infection and its impact on growth of children with hepatitis C Virus [6.1, Issue 1, 2021, Pages 17-23]
  • Pentraxin 3 Pentraxin 3 level as a Biomarker for Diagnosis of Hepatitis C Virus Related Hepatocellular Carcinoma [8.2, Issue 2, 2024, Pages 1-7]
  • Periodontitis Periodontal disease as predictor of chronic liver diseases [4.2, Issue 2, 2020, Pages 57-61]
  • PMN count and hepatorenal syndrome (HRS) The Predictive Factors for Recurrence of Spontaneous Bacterial Peritonitis [2.2, Issue 2, 2018, Pages 25-29]
  • Polymerase inhibitors Evolution of treatment of chronic hepatitis C virus infection by directly acting anti-viral therapeutics: A glimmer of hope [1.1, Issue 1, 2015, Pages 1-11]
  • Portal Hypertension Portal Hypertension, an Overview [4.1, Issue 1, 2019, Pages 15-21]
  • Pregnancy Alpha-Methyldopa-induced hepatitis during pregnancy [2.2, Issue 2, 2018, Pages 15-16]
  • Pregnancy Management of chronic hepatitis B in special populations [4.2, Issue 2, 2020, Pages 63-68]
  • Protease inhibitors Evolution of treatment of chronic hepatitis C virus infection by directly acting anti-viral therapeutics: A glimmer of hope [1.1, Issue 1, 2015, Pages 1-11]

Q

R

  • Receptor interacting protein kinase-1 Anti-cancer activity of hesperidin against hepatocellular carcinoma-induced in rats through upregulation of RIPK1 expression [7.1, Issue 1, 2022, Pages 15-20]
  • Recurrence The Predictive Factors for Recurrence of Spontaneous Bacterial Peritonitis [2.2, Issue 2, 2018, Pages 25-29]
  • Ribavirin Sofosbuvir plus Ribavirin for Treatment-Naïve Chronic HCV Genotype 4 Patients: Real-life Experience [2.1, Issue 1, 2016, Pages 1-8]
  • Ribavirin Assessment of Patient Compliance during treatment of chronic hepatitis C infection using Sofosbuvir and Daclatasvir with or without Ribavirin. [5.2, Issue 2, 2021, Pages 32-39]

S

  • Sarcopenia and pre-sarcopenia Assessment of muscle status and Sarcopenia in patients with liver cirrhosis [4.1, Issue 1, 2019, Pages 23-33]
  • SARS-CoV-2 Intracranial hemorrhage with COVID 19 patient; case report [5.1, Issue 1, 2020, Pages 3-5]
  • SBP The Predictive Factors for Recurrence of Spontaneous Bacterial Peritonitis [2.2, Issue 2, 2018, Pages 25-29]
  • Schistosomiasis The role of interleukin-2 and interleukin-4 in disease progression in patients with schistosomiasis combined with chronic viral hepatitis C and chronic viral hepatitis B [3.2, Issue 2, 2019, Pages 57-64]
  • Schistosomiasis Characterization of hepatocellular carcinoma in Mansoura university Hospitals: A case-control study of risk factors. [6.1, Issue 1, 2021, Pages 38-45]
  • Score Fibrogenic/Angiogenic Linker for Non-invasive assessment of hepatic fibrosis staging in chronic hepatitis C genotype 4 patients [2.1, Issue 1, 2016, Pages 1-14]
  • Seroepidemiology Seroepidemiology and risk factor of hepatitis B and C virus infections in hemodialysis patients in Lomé, Togo. [5.3, Issue 3, 2021, Pages 22-26]
  • Serum ALT Demographics of incidentally diagnosed chronic hepatitis B in teenagers in Bangladesh [1.1, Issue 1, 2015, Pages 1-9]
  • Serum bilirubin Demographics of incidentally diagnosed chronic hepatitis B in teenagers in Bangladesh [1.1, Issue 1, 2015, Pages 1-9]
  • Sofosbuvir Assessment of Patient Compliance during treatment of chronic hepatitis C infection using Sofosbuvir and Daclatasvir with or without Ribavirin. [5.2, Issue 2, 2021, Pages 32-39]
  • Sofosbuvir plus Sofosbuvir plus Ribavirin for Treatment-Naïve Chronic HCV Genotype 4 Patients: Real-life Experience [2.1, Issue 1, 2016, Pages 1-8]
  • Spontaneous Bacterial Peritonitis Spontaneous Bacterial Peritonitis: An Overview [3.1, Issue 1, 2018, Pages 13-17]
  • Spontaneous Bacterial Peritonitis Mini-dose albumin can reduce renal impairment in cirrhotic patients with spontaneous bacterial peritonitis [5.1, Issue 1, 2020, Pages 13-18]
  • Spontaneous Bacterial Peritonitis Macrophage Inflammatory Protein Type 1 Beta as a Novel Diagnostic Marker for Diagnosis of Spontaneous Bacterial Peritonitis [5.2, Issue 2, 2021, Pages 16-20]
  • Spontaneous Bacterial Peritonitis Culture negative neutrocytic ascites versus culture positive spontaneous bacterial peritonitis; Is there a Difference; A Multi-Centric Study [5.3, Issue 3, 2021, Pages 1-7]
  • Spontaneous Bacterial Peritonitis Diagnostic utility of absolute neutrophil count as a new marker of spontaneous bacterial peritonitis; multicenter study [6.3, Issue 3, 2022, Pages 12-18]
  • Spontaneous Bacterial Peritonitis Incidence and predictors of acute oesophageal variceal haemorrhage in patients with spontaneous bacterial peritonitis [7.1, Issue 1, 2022, Pages 1-7]
  • Spontaneous Bacterial Peritonitis Predictors of 30-day hospital readmission in patients with spontaneous bacterial peritonitis, to improve health quality. Prospective cohort [7.3, Issue 3, 2023, Pages 7-14]
  • Spontaneous Bacterial Peritonitis C-reactive protein to albumin ratio: A new score for predicting the recurrence of spontaneous bacterial peritonitis in cirrhotic patients with ascites [8.2, Issue 2, 2024, Pages 6-8]
  • Spontaneous bacterial peritonitis and acute on top of chronic liver failure Infections in cirrhotic patients [4.1, Issue 1, 2019, Pages 5-14]
  • Superinfection Seroprevalence of hepatitis A virus infection in patients with chronic liver diseases: Do we need to vaccinate? [1.1, Issue 1, 2015, Pages 1-9]
  • Sustained viral response Evolution of treatment of chronic hepatitis C virus infection by directly acting anti-viral therapeutics: A glimmer of hope [1.1, Issue 1, 2015, Pages 1-11]
  • Sustained virologic response Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy [4.2, Issue 2, 2020, Pages 69-73]
  • Sustained virologic response Development of Focal segmental glomerulosclerosis 4- years following direct-acting antiviral therapy for hepatitis C virus infection: Case report [6.1, Issue 1, 2021, Pages 1-3]
  • Sustained virologic response Outcomes of direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis [6.1, Issue 1, 2021, Pages 46-53]
  • Sustained virologic response Incidence of hepatocellular carcinoma one year after direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis; A multicenter study [6.2, Issue 2, 2022, Pages 11-17]
  • Systemic Inflammatory Markers Dynamic changes of systemic inflammatory markers and their association with radiologic progression and hepatotoxicity in patients with hepatocellular carcinoma on systemic therapy [9.1, Issue 1, 2025, Pages 1-7]
  • Systemic therapy Dynamic changes of systemic inflammatory markers and their association with radiologic progression and hepatotoxicity in patients with hepatocellular carcinoma on systemic therapy [9.1, Issue 1, 2025, Pages 1-7]

T

  • Teenagers Demographics of incidentally diagnosed chronic hepatitis B in teenagers in Bangladesh [1.1, Issue 1, 2015, Pages 1-9]
  • Tenofovir Outcome of Hepatitis B treatment with oral drugs (Tenofovir and Entecavir) in a tertiary care center in eastern India [8.2, Issue 2, 2024, Pages 17-20]
  • Terlipressin Hepatorenal Syndrome: Update on pathogenesis and management [2.2, Issue 2, 2018, Pages 7-14]
  • Tertiary peritonitis Tertiary peritonitis in patients with cirrhotic ascites; Case report [6.3, Issue 3, 2022, Pages 29-31]
  • Therapy Liver histopathology detects more chronic hepatitis B virus genotype D patients who need to be treated [1.1, Issue 1, 2015, Pages 1-14]
  • Thioredoxin Serum Thioredoxin as a Diagnostic Marker for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 9-15]
  • Togo Genetic Variability of NS5B Region of Hepatitis C Virus in Togo [5.3, Issue 3, 2021, Pages 8-13]
  • Togo Seroepidemiology and risk factor of hepatitis B and C virus infections in hemodialysis patients in Lomé, Togo. [5.3, Issue 3, 2021, Pages 22-26]
  • Transient elastography Comparison between Transient Elastography (FibroScan) and Liver Biopsy for the Diagnosis of Hepatic Fibrosis in Chronic Hepatitis C Patients [2.1, Issue 1, 2016, Pages 1-9]
  • Transient elastography Noninvasive markers for staging fibrosis in chronic hepatitis B patients [2.2, Issue 2, 2018, Pages 17-23]
  • Transient elastography Comparison between transient elastography and other markers for predicting the fibrosis stages of patients with chronic HCV infection in Beni-Suef governorate, Egypt [4.1, Issue 1, 2019, Pages 45-52]
  • Transient elastography Transient Elastography and its Correlation with Biochemical Scores in patients with Metabolic associated fatty liver disease [6.3, Issue 3, 2022, Pages 22-28]
  • Treatment Evolution of treatment of chronic hepatitis C virus infection by directly acting anti-viral therapeutics: A glimmer of hope [1.1, Issue 1, 2015, Pages 1-11]
  • Treatment-naïve Sofosbuvir plus Ribavirin for Treatment-Naïve Chronic HCV Genotype 4 Patients: Real-life Experience [2.1, Issue 1, 2016, Pages 1-8]
  • Treatment response Hepatitis B Surface Antigen Quantitation as a Predictor of Treatment Response in Chronic Hepatitis B [2.1, Issue 1, 2016, Pages 1-11]

U

V

  • Vascular endothelial growth Fibrogenic/Angiogenic Linker for Non-invasive assessment of hepatic fibrosis staging in chronic hepatitis C genotype 4 patients [2.1, Issue 1, 2016, Pages 1-14]
  • VGCCα2δ1 Serum fibroblast growth factor 19 and calcium channel α2δ1 subunit as diagnostic biomarkers for hepatocellular carcinoma [9.1, Issue 1, 2025, Pages 9-14]
  • Viral load Liver histopathology detects more chronic hepatitis B virus genotype D patients who need to be treated [1.1, Issue 1, 2015, Pages 1-14]